Nutex Health (NUTX) 10-Q15 May 232023 Q1 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2023	May 12, 2023
Cover
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-41346
Entity Registrant Name	NUTEX HEALTH INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3363609
Entity Address, Address Line One	6030 S. Rice Ave
Entity Address, Address Line Two	Suite C
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77081
City Area Code	713
Local Phone Number	660-0557
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	NUTX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		656,563,153
Entity Central Index Key	0001479681
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 32,836,535	$ 34,255,264
Accounts receivable	50,977,291	57,777,386
Accounts receivable - related parties	538,283	538,183
Inventories	3,485,445	3,533,285
Prepaid expenses and other current assets	829,553	1,869,806
Total current assets	88,667,107	97,973,924
Property and equipment, net	77,116,496	82,094,352
Operating right-of-use assets	17,454,733	20,466,632
Finance right-of-use assets	208,619,460	192,591,624
Intangible assets, net	20,804,971	21,191,390
Goodwill, net	17,010,637	17,010,637
Other assets	422,926	423,426
Total assets	430,096,330	431,751,985
Current liabilities:
Accounts payable	15,048,720	23,614,387
Accounts payable - related parties	3,925,297	3,915,661
Lines of credit	2,672,893	2,623,479
Current portion of long-term debt	10,456,134	12,546,097
Operating lease liabilities, current portion	1,495,409	1,703,014
Finance lease liabilities, current portion	4,118,170	4,219,518
Accrued expenses and other current liabilities	10,162,166	6,240,813
Total current liabilities	47,878,789	54,862,969
Long-term debt, net	25,108,364	23,051,152
Operating lease liabilities, net	16,634,948	19,438,497
Finance lease liabilities, net	221,394,523	203,619,756
Deferred tax liabilities	9,541,552	10,452,211
Total liabilities	320,558,176	311,424,585
Commitments and contingencies.
Equity:
Common stock, $0.001 par value; 900,000,000 shares authorized; 651,926,125 and 650,223,840 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	651,926	650,224
Additional paid-in capital	460,396,700	458,498,402
Accumulated deficit	(368,433,204)	(363,285,925)
Nutex Health Inc. equity	92,615,422	95,862,701
Noncontrolling interests	16,922,732	24,464,699
Total equity	109,538,154	120,327,400
Total liabilities and equity	$ 430,096,330	$ 431,751,985

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
CONDENSED CONSOLIDATED BALANCE SHEETS
Common stock, par value	$ 0.001	$ 0.001
Common stock authorized	900,000,000	900,000,000
Common stock issued	651,926,125	650,223,840
Common stock outstanding	651,926,125	650,223,840

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue	$ 56,329,417	$ 79,127,242
Operating costs and expenses:
Payroll and benefits	25,836,673	25,610,217
Contract services	9,189,331	4,918,632
Medical supplies	4,023,882	4,259,479
Depreciation and amortization	3,993,747	2,396,861
Other	8,438,061	6,126,557
Total operating costs and expenses	51,481,694	43,311,746
Gross profit	4,847,723	35,815,496
Corporate and other costs:
Facilities closing costs	217,266
Stock-based compensation expense	1,900,000
General and administrative expenses	7,175,544	6,576,523
Total corporate and other costs	9,292,810	6,576,523
Operating income (loss)	(4,445,087)	29,238,973
Interest expense, net	3,140,089	1,855,974
Other expense	247,455	2,380,545
Income (loss) before taxes	(7,832,631)	25,002,454
Income tax expense (benefit)	(910,659)	176,323
Net income (loss)	(6,921,972)	24,826,131
Less: net income (loss) attributable to noncontrolling interests	(1,774,693)	3,383,288
Net income (loss) attributable to Nutex Health Inc.	$ (5,147,279)	$ 21,442,843
Earnings (loss) per common share
Basic earnings per share	$ (0.01)	$ 0.04
Diluted earning per share	$ (0.01)	$ 0.04
Hospital Division
Revenue:
Total revenue	$ 49,288,164	$ 79,127,242
Population Health Management Division
Revenue:
Total revenue	$ 7,041,253

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)	Common Stock	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Noncontrolling Interests	Total
Beginning balance, value at Dec. 31, 2021	$ 592,792	$ 11,742,891	$ 102,315,623	$ 76,929,704	$ 191,581,010
Beginning balance, shares at Dec. 31, 2021	592,791,712
Contributions				3,869,201	3,869,201
Distributions			(27,114,936)	(5,738,045)	(32,852,981)
Net income (loss)			21,442,843	3,383,288	24,826,131
Ending balance, value at Mar. 31, 2022	$ 592,792	11,742,891	96,643,530	78,444,148	187,423,361
End balance, shares at Mar. 31, 2022	592,791,712
Beginning balance, value at Dec. 31, 2022	$ 650,224	458,498,402	(363,285,925)	24,464,699	120,327,400
Beginning balance, shares at Dec. 31, 2022	650,223,840
Deconsolidation of Real Estate Entity				(4,258,133)	(4,258,133)
Common stock issued for exercise of warrants	$ 702	(702)
Common stock issued for exercise of warrants , shares	702,285
Common stock issued	$ 1,000	1,899,000			1,900,000
Common stock issued to Apollo Medical Holdings, Inc., (in shares)	1,000,000
Contributions				28,000	28,000
Distributions				(1,537,141)	(1,537,141)
Net income (loss)			(5,147,279)	(1,774,693)	(6,921,972)
Ending balance, value at Mar. 31, 2023	$ 651,926	$ 460,396,700	$ (368,433,204)	$ 16,922,732	$ 109,538,154
End balance, shares at Mar. 31, 2023	651,926,125

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net income (loss)	$ (6,921,972)	$ 24,826,131
Adjustment to reconcile net income (loss) to net cash from operating activities:
Depreciation and amortization	3,993,747	2,396,861
Amortization of debt issuance costs	6,738
Stock-based compensation expense	1,900,000
Deferred tax expense	(910,659)
Loss on lease termination	58,211
Non-cash lease expense	40,545	58,857
Changes in operating assets and liabilities:
Accounts receivable	6,620,249	2,849,060
Accounts receivable - related party	(100)	1,867,496
Inventories	47,840	(578)
Prepaid expenses and other current assets	1,040,753	131,053
Accounts payable	(8,565,577)	3,871,115
Accounts payable - related party	9,636	(531,066)
Accrued expenses and other current liabilities	3,732,602	272,493
Net cash from operating activities	1,052,013	35,741,422
Cash flows from investing activities:
Acquisitions of property and equipment	(4,376,983)	(8,591,823)
Cash related to deconsolidation of Real Estate Entity	(1,039,157)
Net cash from investing activities	(5,416,140)	(8,591,823)
Cash flows from financing activities:
Proceeds from lines of credit	49,414	2,044,765
Proceeds from notes payable	7,551,506	2,192,309
Repayments of lines of credit		(45,107)
Repayments of notes payable	(2,209,678)	(2,590,917)
Repayments of finance leases	(936,703)	(299,275)
Payment of debt issuance costs		(27,388)
Members' contributions	28,000	3,869,201
Members' distributions	(1,537,141)	(32,852,981)
Net cash from financing activities	2,945,398	(27,709,393)
Net change in cash and cash equivalents	(1,418,729)	(559,794)
Cash and cash equivalents - beginning of the period	34,255,264	36,118,284
Cash and cash equivalents - end of the period	$ 32,836,535	$ 35,558,490

Organization and Operations

Organization and Operations	3 Months Ended
Organization and Operations	Mar. 31, 2023
Organization and Operations
Organization and Operations	Note 1 – Nutex Health Inc. (“Nutex Health” or the “Company”), is a physician-led, healthcare services and operations company with 19 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. Our hospital division implements and operates different innovative health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (“HOPDs”). The population health management division owns and operates provider networks such as independent physician associations (“IPAs”) and offers a cloud-based proprietary technology platform to IPAs which aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers. We employ approximately 1,200 full time employees and partner with over 900 physicians. Our corporate headquarters is based in Houston, Texas. We were incorporated on April 13, 2000 in the state of Delaware. Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc In connection with the Merger Agreement, Nutex Health Holdco LLC entered into certain Contribution Agreements with holders of equity interests (“Nutex Owners”) of subsidiaries and affiliates (the “Nutex Subsidiaries”) pursuant to which such Nutex Owners agreed to contribute certain equity interests in the Nutex Subsidiaries to Nutex Health Holdco LLC in exchange for specified equity interests in Nutex Health Holdco LLC (collectively, the “Contribution Transaction”). Nutex owners having ownership interests representing approximately 84% of the agreed upon aggregate equity value of the Nutex Subsidiaries, agreed to contribute all or a portion of their equity interests, as applicable. Pursuant to the Merger Agreement, each unit representing an equity interest in Nutex Health Holdco LLC issued and outstanding immediately prior to the effective time of the Merger but after the Contribution Transaction (collectively, the “Nutex Membership Interests”) was converted into the right to receive 3.571428575 shares of common stock of Clinigence, or an aggregate of 592,791,712 shares of common stock of Clinigence. After completing the merger, Clinigence was renamed Nutex Health Inc.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2023
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies Basis of presentation. The hospital division includes our healthcare billing and collections organization and hospital entities. In addition, we have financial and operating relationships with multiple professional entities (the “Physician LLCs”) and real estate entities (the “Real Estate Entities”). The Physician LLCs employ the doctors who work in our hospitals. These entities are consolidated by the Company as VIEs because they do not have significant equity at risk, and we have historically provided support to the Physician LLCs in the event of cash shortages and received the benefit of their cash surpluses. The Real Estate Entities own the land and hospital buildings which are leased to our hospital entities. The Real Estate Entities have mortgage loans payable to third parties which are collateralized by the land and buildings. We consolidate the Real Estate Entities as VIEs in instances where our hospital entities are guarantors or co-borrowers under their outstanding mortgage loans. Since the second quarter of 2022, we have deconsolidated 18 Real Estate Entities after the third-party lenders released our guarantees of associated mortgage loans. The Company has no direct or indirect ownership interest in the consolidated Physician LLCs or Real Estate Entities, so 100% of the equity for these entities is shown as noncontrolling interests in the consolidated balance sheets and statements of operations. Many of the Physician LLCs and Real Estate Entities are owned in part and in some cases controlled by related parties including members of our executive management team. The population health management division includes our management services organizations and a healthcare information technology company providing a cloud-based platform for healthcare organizations. In addition, Associated Hispanic Physicians of So. California (“AHISP”), an IPA entity that is not owned by us, but is consolidated as a VIE of our wholly-owned subsidiary AHP Health Management Services Inc. (“AHP”) since AHP is the primary beneficiary of its operations and has 100% control of AHISP’s operations through its management services agreement with AHISP. All significant intercompany balances and transactions have been eliminated in consolidation. Interim financial statements. These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting Accordingly, they do not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). The unaudited condensed consolidated financial statements include all material adjustments of a normal recurring nature that, in the opinion of management, are necessary for a fair presentation of the results of operations for the interim periods presented. These interim financial statements should be read together with the consolidated financial statements and notes thereto included in our audited financial statements for the years ended December 31, 2022 and 2021. Use of estimates. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include (i) estimates of net revenue and accounts receivable, (ii) fair value of acquired assets and liabilities in business combinations and (iii) impairment of long-lived assets and goodwill. Actual results could differ from those estimates. Fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. We classify fair value balances based on the classification of the inputs used to calculate the fair value of a transaction. The three levels related to fair value measurements are as follows: Level 1 — Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. The estimated fair value of accounts receivable, accounts payable, accrued expenses and notes payable approximate the carrying amount due to the relatively short maturity or time to maturity of these instruments. Accounts receivable and payable with related parties may not be arms-length transactions and therefore, may not reflect fair value. Except for the initial valuation of intangible assets in connection with the reverse business combination with Clinigence discussed in Note 3 and the impairment of goodwill discussed above, there were no assets or liabilities that were re-measured at fair value on a non-recurring basis during the periods presented. Segment reporting. A public company is required to report descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet established criteria. The Company operates three reportable segments – the hospital division, the population health management division and the real estate division. The real estate division is comprised of the Real Estate Entities. Reclassifications . Financial statements presented for prior periods include reclassifications that were made to conform to the current year presentation. Recent accounting pronouncements. There are no new accounting pronouncements that are expected to have a material impact on the condensed consolidated financial statements.

Merger of Nutex Health Holdco L

Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc	3 Months Ended
	Mar. 31, 2023
Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc
Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc	Note 3 - Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc. The merger of Nutex Health Holdco LLC and Clinigence was completed pursuant to the Merger Agreement on April 1, 2022. As discussed above, the merger was accounted for as a reverse business combination with Nutex Health Holdco LLC as the accounting acquirer and Clinigence as the accounting acquiree. The fair value of purchase consideration transferred on the closing date includes the value of the shares of the combined company owned by Clinigence shareholders at closing of the merger and the fair value of Clinigence’s outstanding and exercisable common stock options and warrants as determined using a Black-Scholes valuation model. The fair value per share of Clinigence’s common stock was $6.40; its traded closing price on April 1, 2022. Total consideration in the merger is shown below: Fair value of Clinigence common shares at $6.40 per share (50,961,109 shares) $ 326,151,098 Fair value of Clinigence outstanding common stock options and warrants 110,543,915 Total consideration $ 436,695,013 The following is the allocation of the total purchase consideration to acquired assets and assumed liabilities including the fair value of identified intangible assets as determined by independent valuation (a level 3 measurement): Cash and cash equivalents $ 12,716,228 Accounts receivable, net 2,127,076 Prepaid expenses and other current assets 127,384 Property and equipment, net 14,793 Right of use asset, net 86,989 Intangible assets, net 21,668,000 Goodwill 414,006,378 Accounts payable and accrued expenses (3,966,100) Deferred revenue (92,111) Convertible notes payable, net (3,771,858) Term note payable (674,526) Lease liability (91,238) Deferred tax liability (5,456,002) Assets acquired $ 436,695,013 We made a retrospective change in the valuation of options and warrants assumed by us as part of the total consideration in the merger. This change reduced the fair value of consideration paid and goodwill by $10.3 million. The intangible assets denoted above each have definite lives. These intangible assets are being amortized over their estimated useful lives of 5 to 16 years. Goodwill arising from the reverse business combination is not tax-deductible. As discussed above, we recognized a non-cash impairment charge of $398.1 million in 2022 to reduce the carrying amount of goodwill arising in the reverse business combination. The results of operations of Clinigence have been included in the Company’s consolidated financial statements since the April 1, 2022 merger date. We expensed $3.9 million of acquisition-related costs for the merger in 2022. These costs consisted principally of legal, accounting and other professional fees for the transaction. Supplemental Pro Forma Information – The supplemental pro forma financial information presented below is for illustrative purposes only and is not necessarily indicative of the financial position or results of operations that would have been realized if the merger with Clinigence had been completed on the date indicated, nor is it indicative of future operating results or financial position. The pro forma adjustments are based upon currently available information and certain assumptions that management believes are reasonable under the circumstances. The supplemental pro forma financial information reflects pro forma adjustments to present the combined pro forma results of operations as if the acquisition had occurred on January 1, 2021, to give effect to certain events that management believes to be directly attributable to the acquisition. These pro forma adjustments primarily include an increase to depreciation and amortization expense that would have been recognized due to acquired tangible and intangible assets. The supplemental pro forma financial information is as follows: Three Months Ended March 31, 2022 Revenue $ 85,336,417 Net income attributable to Nutex Health Inc. 7,180,154 Basic earnings per share 0.01 Diluted earning per share 0.01 The pro forma income above includes $14.2 million of one-time stock-based compensation expense related to the merger transaction. Pro forma data does not purport to be indicative of the results that would have been obtained had these events actually occurred at the beginning of the period presented and is not intended to be a projection of future results.

Revenue

Revenue	3 Months Ended
Revenue	Mar. 31, 2023
Revenue
Revenue	Note 4 – Revenue We disaggregate revenue from contracts with customers into types of services or products, consistent with our reportable segments, as follows: Three Months Ended March 31, 2023 2022 Hospital Division: Net patient service revenue $ 54,137,235 $ 79,127,242 Management fees (4,849,071) - Total Hospital Division revenue 49,288,164 79,127,242 Population Health Management Division: Capitation revenue, net 6,051,574 - Management fees 719,626 - SaaS revenue 270,053 - Total Population Health Management Division revenue 7,041,253 - Total revenue $ 56,329,417 $ 79,127,242 Net patient service revenue The following tables present the allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage: Three Months Ended March 31, 2023 2022 Insurance 93% 96% Self pay 4% 3% Workers compensation 1% 1% Medicare/Medicaid 2% 0% Total 100% 100% Contract balances

Property and Equipment

Property and Equipment	3 Months Ended
Property and Equipment	Mar. 31, 2023
Property and Equipment
Property and Equipment	Note 5 - Property and Equipment The principal categories of property and equipment, net are summarized as follows: Useful March 31, December 31, Life (years) 2023 2022 Buildings and improvements 39 $ 9,086,826 $ 8,521,996 Land - 2,650,670 3,721,576 Leasehold improvements 10-39 28,855,241 28,855,239 Construction in progress - 13,560,583 19,389,329 Medical equipment 10 29,220,485 28,744,664 Office furniture and equipment 7 2,860,680 2,860,680 Computer hardware and software 5 3,221,577 1,713,434 Vehicles 5 135,590 135,590 Signage 10 1,163,722 1,163,722 Total cost 90,755,374 95,106,230 Less: accumulated depreciation (13,638,878) (13,011,878) Total property and equipment, net $ 77,116,496 $ 82,094,352 We deconsolidated 17 Real Estate Entities in the second quarter of 2022 and one Real Estate Entity in the first quarter of 2023. Refer to Note 18. Depreciation and amortization of property and equipment for the three months ended March 31, 2023 and 2022 totaled $1,123,053 and $1,469,198 respectively.

Intangible Assets

Intangible Assets	3 Months Ended
Intangible Assets	Mar. 31, 2023
Intangible Assets
Intangible Assets	Note 6 – Intangible Assets The following tables provide detail of the Company’s intangible assets: Gross Accumulated Net Carrying Weighted Average March 31, 2023 Carrying Amount Amortization Amount Useful Life (in years) Amortizing intangible assets: Member relationships $ 16,899,000 $ 1,126,599 $ 15,772,401 15 Management contracts 2,021,000 126,313 1,894,687 16 Customer contracts 914,000 60,933 853,067 15 Trademarks 1,425,000 150,033 1,274,967 7-12 PHP technology 409,000 81,800 327,200 5 Indefinite life intangible - license 682,649 - 682,649 - Total $ 22,350,649 $ 1,545,678 $ 20,804,971 December 31, 2022 Amortizing intangible assets: Member relationships $ 16,899,000 $ 844,950 $ 16,054,050 15 Management contracts 2,021,000 94,734 1,926,266 16 Customer contracts 914,000 45,700 868,300 15 Trademarks 1,425,000 112,525 1,312,475 7-12 PHP technology 409,000 61,350 347,650 5 Indefinite life intangible - license 682,649 - 682,649 - Total $ 22,350,649 $ 1,159,259 $ 21,191,390 Amortization of intangible assets for the three months ended March 31, 2023 and 2022 totaled $386,419 and $0, respectively.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
Accrued Expenses and Other Current Liabilities	Mar. 31, 2023
Accrued Expenses and Other Current Liabilities
Accrued Expenses and Other Current Liabilities	Note 7 – Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: March 31, December 31, 2023 2022 Accrued wages and benefits $ 5,901,561 $ 4,235,167 Accrued taxes 3,461,054 1,029,790 Accrued other 799,551 975,856 Total accrued expenses and other current liabilities $ 10,162,166 $ 6,240,813

Debt

Debt	3 Months Ended
Debt	Mar. 31, 2023
Debt
Debt	Note 8 – Debt The Company’s outstanding debt is shown in the following table: Maturity Interest March 31, December 31, Dates Rates 2023 2022 Term loans secured by all assets 04/2023 - 11/2030 3.25 - 6.00% $ 10,965,545 $ 11,341,934 Term loans secured by property and equipment 01/2024 - 10/2029 4.19 - 6.90% 10,815,089 9,299,197 Line of credit secured by all assets 04/2023 - 11/2025 4.50 - 6.50% 2,672,894 2,623,479 Term loans of consolidated Real Estate Entities 08/2023 - 03/2037 3.59 - 4.80% 13,886,997 15,068,920 Total 38,340,525 38,333,530 Less: unamortized debt issuance costs 103,134 112,802 Less: short-term lines of credit 2,672,893 2,623,479 Less: current portion of long-term debt 10,456,134 12,546,097 Total long-term debt $ 25,108,364 $ 23,051,152 Term loans and lines of credit Certain outstanding debt arrangements require minimum debt service coverage ratios and other financial covenants. At March 31, 2023, we were not in compliance with the debt service coverage ratio for one term loan with an outstanding balance of $1.0 million. This balance has been included in current liabilities. At March 31, 2023, we had remaining availability of $3.1 million under outstanding lines of credit. Convertible notes payable. The convertible notes payable were fully converted into 3,474,430 shares of common stock at a conversion price of $1.55 per share before their maturity on July 31, 2022

Leases

Leases	3 Months Ended
Leases	Mar. 31, 2023
Leases
Leases	Note 9 – Leases We have entered into hospital property, office and equipment rental agreements with various lessors including related parties. The following tables disclose information about our leases of property and equipment: Three Months Ended March 31, 2023 2022 Operating lease cost $ 948,515 $ 692,669 Finance lease cost: Amortization of right-of-use assets $ 2,484,275 $ 927,664 Interest on lease liabilities 2,688,520 980,619 Total finance lease cost $ 5,172,795 $ 1,908,283

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2023
Commitments and Contingencies
Commitments and Contingencies	Note 10 – Commitments and Contingencies Litigation

Stock-based Compensation

Stock-based Compensation	3 Months Ended
Stock-based Compensation	Mar. 31, 2023
Stock-based Compensation
Stock-based Compensation	Note 11 – Stock-based Compensation In 2022, the Company adopted the Amended and Restated Nutex Health Inc. 2022 Equity Incentive Plan (the “2022 Plan”). The maximum aggregate number of shares that may be issued under the 2022 Plan is 5,000,000 shares, subject to increases on January 1st of each calendar year through January 1, 2027 of up to 5% annually at the discretion of the compensation committee of our Board of Directors. A total of 2,416,221 shares were available for issuance under the 2022 Plan at March 31, 2023. Awards granted under the 2022 Plan have a ten-year term and may be incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units or performance shares. The awards are granted at an exercise price equal to the fair market value on the date of grant and generally vest over a four-year period. Obligations for under-construction and ramping hospitals. ● With respect to ramping hospitals, 24 months after the opening date (the “Determination Date”) of the applicable ramping hospital, such owner is eligible to receive such owner’s pro rata share of a number of shares of Company Common Stock equal to (i) the trailing twelve months earnings before interest, taxes, depreciation and amortization on the respective Determination Date, multiplied by (ii) 10 , (iii) minus the initial equity value received at the Closing of the Merger, and (iv) minus such owner’s pro rata share of the aggregate debt of the applicable ramping hospital outstanding as of the closing of the Merger. The number of additional shares to be issued will be determined based on the greater of (a) the price of the Company’s common stock at the time of determination or (b) $2.80 . ● With respect to under construction hospitals, contributing owners of under construction hospitals will be eligible to receive, on the Determination Date, such owner’s pro rata share of a number of shares of Company common stock equal to (a)(i) the trailing twelve months earnings before interest, taxes, depreciation and amortization as of the Determination Date multiplied by (ii) 10 , minus (iii) the aggregate amount of such owner’s capital contribution to the under construction hospital, minus (iv) such owner’s pro rata share of the aggregate debt of the applicable under construction hospital outstanding as of the Closing of the Merger, divided by (b) the greater of (i) the price of the Company common stock at the time of determination or (ii) $2.80 . We have not recognized any expense for this stock-based compensation based on our current estimates of future obligations to the contributing owners. Options Weighted Average Options Weighted Average Remaining Contractual Outstanding Exercise Price Life (Years) Options outstanding at December 31, 2022 5,147,770 $ 2.30 7.60 Options exercised - - Options cancelled - - Options outstanding at March 31, 2023 5,147,770 $ 2.32 7.35 Options outstanding as of March 31, 2023 consisted of: Expiration Number Number Exercise Date Outstanding Exercisable Price March 15, 2025 157,196 157,196 $ 4.47 January 27, 2027 180,000 180,000 1.50 May 11, 2027 350,000 350,000 1.50 June 6, 2027 3,600 3,600 36.25 August 16, 2027 25,000 25,000 2.51 January 28, 2028 180,000 180,000 1.61 January 27, 2030 296,865 296,865 1.50 February 28, 2030 95,794 95,794 1.25 June 30, 2030 117,056 117,056 1.45 August 4, 2029 40,480 40,480 5.56 January 28, 2031 1,000,000 1,000,000 1.61 February 28, 2031 200,000 200,000 2.00 September 9, 2031 1,934,779 1,934,779 2.75 September 9, 2031 410,000 410,000 2.75 December 17, 2031 157,000 157,000 3.50 Total 5,147,770 5,147,770

Equity

Equity	3 Months Ended
Equity	Mar. 31, 2023
Equity
Equity	Note 12 – Equity We are authorized to issue up to a total of 900,000,000 shares of common stock having a par value of $0.001 per share. Holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders and to receive ratably in proportion to the shares of common stock held by them any dividends declared from time to time by the board of directors. Our common stock has no preferences or rights of conversion, exchange, pre-exemption or other subscription rights. Common Stock Issued ● In March 2023, we issued 1,000,000 common shares to Apollo Medical Holdings, Inc. for IPA managerial services. We recognized $1.9 million of stock-based compensation expense for this issuance. This expense should have been recognized on December 31, 2022. However, we consider this expense not material for revision and thus, is an out-of-period adjustment in this quarter’s financial statements. ● At the time of the Merger, Clinigence had 50,961,109 common shares outstanding. These amounts are shown as issued by us in the presentation of consolidated financial statements as the accounting acquiror. Warrants. Weighted Average Warrants Weighted Average Remaining Contractual Outstanding Exercise Price Life (years) Warrants outstanding at December 31, 2022 11,033,015 $ 1.96 3.80 Warrants exercised (806,453) 1.55 Warrants expired (1,500) 1.55 Warrants outstanding at March 31, 2023 10,225,062 $ 1.99 3.53 In the first quarter of 2023, 702,285 shares of common stock were issued in satisfaction of cashless exercises of warrants to purchase of 806,453 shares of common stock. Warrants outstanding as of March 31, 2023 consisted of: Expiration Number Number Exercise Date Outstanding Exercisable Price April 27, 2023 1,500 1,500 $ 25.00 December 31, 2024 554,873 554,873 6.67 October 31, 2025 16,250 16,250 1.25 October 31, 2025 1,566,451 1,566,451 1.55 February 26, 2026 288,235 288,235 4.00 July 31, 2026 2,532,900 2,532,900 1.55 February 1, 2027 650,000 650,000 1.55 May 31, 2027 4,614,853 4,614,853 1.75 Total 10,225,062 10,225,062

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2023
Income Taxes
Income Taxes	Note 13 – Income Taxes Income tax provisions for interim quarterly periods are generally based on an estimated annual effective income tax rate calculated separately from the effect of significant, infrequent or unusual items related specifically to interim periods. The income tax impact of discrete items is recognized in the period these occur. In periods before the merger with Clinigence, Nutex Health Holdco LLC and the Nutex Subsidiaries were pass-through entities treated as partnerships for U.S. federal income tax purposes. No provision for federal income taxes was provided for these periods as federal taxes were obligations of these companies’ members. After the merger, Nutex Health Holdco LLC became a wholly-owned subsidiary of Clinigence and is included in its future consolidated corporate tax filings. Our effective tax rate for the three months ended March 31, 2023 was 11.63%.

Earnings per Share

Earnings per Share	3 Months Ended
Earnings per Share	Mar. 31, 2023
Earnings per Share
Earnings per Share	Note 14 – Earnings per Share The following is the computation of earnings (loss) per basic and diluted share: Three Months Ended March 31, 2023 2022 Amounts attributable to Nutex Health Inc.: Numerator- Net income (loss) attributable to common stockholders $ (5,147,279) $ 21,442,843 Denominator: Weighted average shares used to compute basic and diluted EPS 650,915,693 592,791,712 Earnings (loss) per share: Basic $ (0.01) $ 0.04 Diluted $ (0.01) $ 0.04 The computation of diluted earnings per common share excludes the 5,147,770 common stock options and 10,225,062 warrants for the three months ended March 31, 2023. The dilutive effect of the assumed exercise of outstanding options and warrants was calculated using the treasury stock method.

Supplemental Cash Flows Informa

Supplemental Cash Flows Information	3 Months Ended
Supplemental Cash Flows Information	Mar. 31, 2023
Supplemental Cash Flows Information
Supplemental Cash Flows Information	Note 15 - Supplemental Cash Flows Information Three Months Ended March 31, 2023 2022 Cash paid for interest $ 430,643 $ 875,355 Cash paid for income taxes - 18,473 Non-cash investing and financing activities: Financed capital expenditures 2,709,019 - Acquisition of finance leases 18,798,667 9,937,104 Termination of operating and finance leases 2,818,498 - Exercise of warrants on cashless basis 702 - Issuance of common stock to Apollo Medical Holdings, Inc. 1,900,000 - Deconsolidation of Real Estate Entity 4,258,133 -

Segment Information

Segment Information	3 Months Ended
Segment Information	Mar. 31, 2023
Segment Information
Segment Information	Note 16 – Segment Information We report the results of our operations as three segments in our consolidated financial statements: (i) the hospital division, (ii) the population health management division and (ii) the real estate division. The determination of our reporting segments was made on the basis of our strategic priorities, which corresponds to the manner in which our Chief Executive Officer, as our chief operating decision maker, reviews and evaluates operating performance to make decisions about resources to be allocated. We evaluate the performance of our reportable segments based on, among other measures, operating income, which is defined as income before interest expense, other income (expense), and taxes. Corporate costs primarily include expenses for support functions and salaries and benefits for corporate employees and are excluded from segment operating results. Reportable segment information, including intercompany transactions, is presented below: Three Months Ended March 31, 2023 2022 Revenue from external customers: Hospital division $ 49,288,164 $ 79,127,242 Population health management division 7,041,253 - Total revenue $ 56,329,417 $ 79,127,242 Segment operating income: Hospital division 4,778,637 35,815,496 Population health management division 69,086 - Total segment operating income $ 4,847,723 $ 35,815,496 Capital expenditures: Hospital division 4,376,983 2,365,359 Real estate division - 6,226,464 Total capital expenditures $ 4,376,983 $ 8,591,823 Revenue from inter-segment activities: Real estate division $ 258,015 $ 4,045,969 Depreciation and amortization: Hospital division 3,564,022 2,396,861 Population health management division 388,047 - Real estate division 41,678 - Total depreciation and amortization $ 3,993,747 $ 2,396,861

Related Party Transactions

Related Party Transactions	3 Months Ended
Related Party Transactions	Mar. 31, 2023
Related Party Transactions
Related Party Transactions	Note 17 – Related Party Transactions Related party transactions included the following: ● The Physician LLCs employ the doctors who work in our hospitals. We have no direct ownership interest in these entities but they are owned and, in some instances, controlled by related parties including our CEO, Dr. Thomas Vo. The Physician LLCs are consolidated by the Company as VIEs because they do not have significant equity at risk, and we have historically provided support to them in the event of cash shortages and received the benefit of their cash surpluses. The Physician LLCs had outstanding obligations to their member owners, who are also Company stockholders, totaling $2,488,212 at March 31, 2023 and $2,058,701 at December 31, 2022 reported within accounts payable – related party in our consolidated balance sheets. ● Most of our hospital division facilities are leased from real estate entities which are owned by related parties. These leases are typically on a triple net basis where our hospital division is responsible for all operating costs, repairs and taxes on the facilities. Our obligations under these leases are presented in Note 9. During the three months ended March 31, 2023, we made cash payments for these lease obligations totaling $3,519,345 . Cash payments for these lease obligations made in the three months ended March 31, 2022 totaled $2,883,681 . ● We consolidate Real Estate Entities as VIEs when they do not have sufficient equity at risk and our hospital entities are guarantors or co-borrowers under their outstanding mortgage loans. The consolidated Real Estate Entities have mortgage loans payable to third parties which are collateralized by the land and buildings. We have no direct ownership interest in these entities but they are owned and, in some instances, controlled by related parties including our CEO. We deconsolidated 17 Real Estate Entities in the second quarter of 2022 and one Real Estate Entity in the first quarter of 2023. At March 31, 2023, two Real Estate Entities continue to be consolidated in our financial statements. In connection with the merger with Clinigence, we forgave certain amounts due from Real Estate Entities for past advances made by us. We recognized net expense totaling $553,259 in the three months ended March 31, 2022 as other expense in the consolidated statements of operations. No such expense was recognized subsequently. ● Accounts receivable – related party included $538,259 at March 31, 2023 and $538,184 at December 31, 2022 due from noncontrolling interest owners of consolidated ER Entities. ● Micro Hospital Holding LLC, an affiliate controlled by our CEO made advances to one of our hospital facilities, SE Texas ER. These advances totaled $1,424,948 at March 31, 2023 and $1,424,948 at December 31, 2022 and are reported as accounts payable – related party in our consolidated balance sheets. The advances have no stated maturity and bear no interest. ● Accounts payable – related party in our consolidated balance sheets included $12,136 at March 31, 2023 and $2,500 at December 31, 2022 for reimbursement of expenses incurred on our behalf. ● We provide managerial services to emergency centers owned and, in some instances, controlled by related parties including an entity controlled by our CEO. We recognized $158,851 of managerial fees within the hospital division in the three months ended March 31, 2023 for these services. In the three months ended March 31, 2022, we recognized $412,554 of revenue for these services. ● Two of our ER Entities are obligated under managerial services agreements with related parties commencing in 2022. Payments under these agreements totaled $336,000 for the three months ended March 31, 2023 and $323,194 for the three months ended March 31, 2022.

Variable Interest Entities

Variable Interest Entities	3 Months Ended
Variable Interest Entities	Mar. 31, 2023
Variable Interest Entities
Variable Interest Entities	Note 18 – Variable Interest Entities The following tables provide the balance sheet amounts for consolidated VIEs: March 31, 2023 Real Estate Physician AHISP Entities LLCs IPA Current assets $ 4,671,762 $ 6,288,095 $ 8,016,463 Property and equipment, net 10,975,277 3,668 - Other long-term assets 19,634,442 - 16,254,462 Total assets $ 35,281,481 $ 6,291,763 $ 24,270,925 Current liabilities 1,038,381 5,400,568 24,240,245 Long-term liabilities 13,838,569 - 30,680 Total liabilities 14,876,950 5,400,568 24,270,925 Equity 20,404,531 891,195 - Total liabilities and equity $ 35,281,481 $ 6,291,763 $ 24,270,925 December 31, 2022 Real Estate Physician AHISP Entities LLCs IPA Current assets $ 3,466,811 $ 6,915,710 $ 6,641,448 Property and equipment, net 16,726,986 3,668 - Long-term assets 19,647,148 - 16,553,040 Total assets $ 39,840,945 $ 6,919,378 $ 23,194,488 Current liabilities 2,326,335 4,831,617 23,163,808 Long-term liabilities 15,019,633 - 30,680 Total liabilities 17,345,968 4,831,617 23,194,488 Equity 22,494,977 2,087,761 - Total liabilities and equity $ 39,840,945 $ 6,919,378 $ 23,194,488 The assets of each of the ER Entities may only be used to settle the liabilities of that entity or its consolidated VIEs and may not be required to be used to settle the liabilities of any of the other ER Entities, other VIEs, or corporate entity. Additionally, the assets of corporate entities cannot be used to settle the liabilities of VIEs. The Company has aggregated all of the Physician LLCs and Real Estate Entities into two categories above, because they have similar risk characteristics, and presenting distinct financial information for each VIE would not add more useful information. Real Estate Entities are consolidated by the Company as VIEs because they do not have sufficient equity at risk and our hospital entities are guarantors of their outstanding mortgage loans. We have been working with the third-party lenders to remove our guarantees of their outstanding mortgage loans. As these guarantees are released, the associated Real Estate Entity no longer qualifies as a VIE and is deconsolidated. We deconsolidated 17 Real Estate Entities in the second quarter of 2022 and one Real Estate Entity in the first quarter of 2023. There was no gain or loss on the deconsolidation of these entities. As of March 31, 2023, two Real Estate Entities continue to be consolidated in our financial statements. At the date we deconsolidated these Real Estate Entities in the second quarter of 2022, they had $2,421,212 of cash, $98,086,690 of fixed assets (principally land and building), $533,874 of other assets, $69,638,778 of liabilities (principally mortgage indebtedness) and $31,402,998 of equity reported as noncontrolling interests. The Real Estate Entity we deconsolidated in the first quarter of 2023 had $1,039,156 of cash, $8,420,537 of fixed assets (principally land and building), $179,846 of other assets, $5,381,316 of liabilities (principally mortgage indebtedness) and $4,258,133 million of equity reported as noncontrolling interests as of the date of deconsolidation.

Subsequent Events

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2023
Subsequent Events
Subsequent Events	Note 19 - Subsequent Events The Company has evaluated subsequent events through the filing of this report and determined that there have been no events that have occurred that would require adjustments to our disclosures in the consolidated financial statements except for the transactions described below: Yorkville Transaction and Conversion. 18-months At the request and sole discretion of Yorkville, such Pre-Paid Advances will be correspondingly reduced upon the issuance of our Common Stock to Yorkville at a Purchase Price equal to (a) $1.00 in respect of the initial Pre-Paid Advance, and (b) with respect to each subsequent Pre-Paid Advance the lower of (i) 100% of the volume weighted average price (VWAP) of the Company’s common stock on the trading day immediately preceding the closing of such Pre- Paid Advance or (ii) 92.0% of the average of the two lowest daily VWAP of the shares during the seven trading days immediately prior to each Pre-Paid Advance, subject to a floor price of $0.1851 per share. In connection with the execution of the PPA, Yorkville paid to the Company an initial Pre-Paid Advance amount of $15 million ($12.8 million before expenses) and agreed to pay an additional $10 million on the earlier of June 10, 2023, or the date upon which the outstanding balance on the initial $15 million has been reduced below $1 million, in each case, as long as the volume weighted average price (VWAP) for the ten Subsequent to the end of the period through the date of the report, in connection with the PPA, Yorkville converted $2,000,000 of principal balance to 3,856,267 shares of common stock. The stock issued was determined based on the terms of the PPA. Restricted Stock Awards. to certain employees. The Stock Issuance. * * * * *

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2023
Summary of Significant Accounting Policies
Basis of presentation	Basis of presentation. The hospital division includes our healthcare billing and collections organization and hospital entities. In addition, we have financial and operating relationships with multiple professional entities (the “Physician LLCs”) and real estate entities (the “Real Estate Entities”). The Physician LLCs employ the doctors who work in our hospitals. These entities are consolidated by the Company as VIEs because they do not have significant equity at risk, and we have historically provided support to the Physician LLCs in the event of cash shortages and received the benefit of their cash surpluses. The Real Estate Entities own the land and hospital buildings which are leased to our hospital entities. The Real Estate Entities have mortgage loans payable to third parties which are collateralized by the land and buildings. We consolidate the Real Estate Entities as VIEs in instances where our hospital entities are guarantors or co-borrowers under their outstanding mortgage loans. Since the second quarter of 2022, we have deconsolidated 18 Real Estate Entities after the third-party lenders released our guarantees of associated mortgage loans. The Company has no direct or indirect ownership interest in the consolidated Physician LLCs or Real Estate Entities, so 100% of the equity for these entities is shown as noncontrolling interests in the consolidated balance sheets and statements of operations. Many of the Physician LLCs and Real Estate Entities are owned in part and in some cases controlled by related parties including members of our executive management team. The population health management division includes our management services organizations and a healthcare information technology company providing a cloud-based platform for healthcare organizations. In addition, Associated Hispanic Physicians of So. California (“AHISP”), an IPA entity that is not owned by us, but is consolidated as a VIE of our wholly-owned subsidiary AHP Health Management Services Inc. (“AHP”) since AHP is the primary beneficiary of its operations and has 100% control of AHISP’s operations through its management services agreement with AHISP. All significant intercompany balances and transactions have been eliminated in consolidation.
Interim financial statements	Interim financial statements. These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting Accordingly, they do not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). The unaudited condensed consolidated financial statements include all material adjustments of a normal recurring nature that, in the opinion of management, are necessary for a fair presentation of the results of operations for the interim periods presented. These interim financial statements should be read together with the consolidated financial statements and notes thereto included in our audited financial statements for the years ended December 31, 2022 and 2021.
Use of estimates	Use of estimates. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include (i) estimates of net revenue and accounts receivable, (ii) fair value of acquired assets and liabilities in business combinations and (iii) impairment of long-lived assets and goodwill. Actual results could differ from those estimates.
Fair value measurements	Fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. We classify fair value balances based on the classification of the inputs used to calculate the fair value of a transaction. The three levels related to fair value measurements are as follows: Level 1 — Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. The estimated fair value of accounts receivable, accounts payable, accrued expenses and notes payable approximate the carrying amount due to the relatively short maturity or time to maturity of these instruments. Accounts receivable and payable with related parties may not be arms-length transactions and therefore, may not reflect fair value. Except for the initial valuation of intangible assets in connection with the reverse business combination with Clinigence discussed in Note 3 and the impairment of goodwill discussed above, there were no assets or liabilities that were re-measured at fair value on a non-recurring basis during the periods presented.
Segment reporting	Segment reporting. A public company is required to report descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet established criteria. The Company operates three reportable segments – the hospital division, the population health management division and the real estate division. The real estate division is comprised of the Real Estate Entities.
Reclassifications	Reclassifications . Financial statements presented for prior periods include reclassifications that were made to conform to the current year presentation.
Recent accounting pronouncements	Recent accounting pronouncements. There are no new accounting pronouncements that are expected to have a material impact on the condensed consolidated financial statements.

Merger of Nutex Health Holdco_2

Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc (Tables)	3 Months Ended
	Mar. 31, 2023
Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc
Schedule of consideration	Fair value of Clinigence common shares at $6.40 per share (50,961,109 shares) $ 326,151,098 Fair value of Clinigence outstanding common stock options and warrants 110,543,915 Total consideration $ 436,695,013
Schedule of acquired assets and assumed liabilities	Cash and cash equivalents $ 12,716,228 Accounts receivable, net 2,127,076 Prepaid expenses and other current assets 127,384 Property and equipment, net 14,793 Right of use asset, net 86,989 Intangible assets, net 21,668,000 Goodwill 414,006,378 Accounts payable and accrued expenses (3,966,100) Deferred revenue (92,111) Convertible notes payable, net (3,771,858) Term note payable (674,526) Lease liability (91,238) Deferred tax liability (5,456,002) Assets acquired $ 436,695,013
Schedule of pro forma financial information	Three Months Ended March 31, 2022 Revenue $ 85,336,417 Net income attributable to Nutex Health Inc. 7,180,154 Basic earnings per share 0.01 Diluted earning per share 0.01

Revenue (Tables)

Revenue (Tables)	3 Months Ended
Revenue (Tables)	Mar. 31, 2023
Revenue
Schedule of disaggregate revenue	Three Months Ended March 31, 2023 2022 Hospital Division: Net patient service revenue $ 54,137,235 $ 79,127,242 Management fees (4,849,071) - Total Hospital Division revenue 49,288,164 79,127,242 Population Health Management Division: Capitation revenue, net 6,051,574 - Management fees 719,626 - SaaS revenue 270,053 - Total Population Health Management Division revenue 7,041,253 - Total revenue $ 56,329,417 $ 79,127,242
Schedule of allocation of the estimated transaction price	Three Months Ended March 31, 2023 2022 Insurance 93% 96% Self pay 4% 3% Workers compensation 1% 1% Medicare/Medicaid 2% 0% Total 100% 100%

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
Property and Equipment (Tables)	Mar. 31, 2023
Property and Equipment
Schedule of property and equipment	Useful March 31, December 31, Life (years) 2023 2022 Buildings and improvements 39 $ 9,086,826 $ 8,521,996 Land - 2,650,670 3,721,576 Leasehold improvements 10-39 28,855,241 28,855,239 Construction in progress - 13,560,583 19,389,329 Medical equipment 10 29,220,485 28,744,664 Office furniture and equipment 7 2,860,680 2,860,680 Computer hardware and software 5 3,221,577 1,713,434 Vehicles 5 135,590 135,590 Signage 10 1,163,722 1,163,722 Total cost 90,755,374 95,106,230 Less: accumulated depreciation (13,638,878) (13,011,878) Total property and equipment, net $ 77,116,496 $ 82,094,352

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
Intangible Assets (Tables)	Mar. 31, 2023
Intangible Assets
Schedule of intangible assets	Gross Accumulated Net Carrying Weighted Average March 31, 2023 Carrying Amount Amortization Amount Useful Life (in years) Amortizing intangible assets: Member relationships $ 16,899,000 $ 1,126,599 $ 15,772,401 15 Management contracts 2,021,000 126,313 1,894,687 16 Customer contracts 914,000 60,933 853,067 15 Trademarks 1,425,000 150,033 1,274,967 7-12 PHP technology 409,000 81,800 327,200 5 Indefinite life intangible - license 682,649 - 682,649 - Total $ 22,350,649 $ 1,545,678 $ 20,804,971 December 31, 2022 Amortizing intangible assets: Member relationships $ 16,899,000 $ 844,950 $ 16,054,050 15 Management contracts 2,021,000 94,734 1,926,266 16 Customer contracts 914,000 45,700 868,300 15 Trademarks 1,425,000 112,525 1,312,475 7-12 PHP technology 409,000 61,350 347,650 5 Indefinite life intangible - license 682,649 - 682,649 - Total $ 22,350,649 $ 1,159,259 $ 21,191,390

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
Accrued Expenses and Other Current Liabilities (Tables)	Mar. 31, 2023
Accrued Expenses and Other Current Liabilities
Schedule of accrued expenses and other current liabilities	March 31, December 31, 2023 2022 Accrued wages and benefits $ 5,901,561 $ 4,235,167 Accrued taxes 3,461,054 1,029,790 Accrued other 799,551 975,856 Total accrued expenses and other current liabilities $ 10,162,166 $ 6,240,813

Debt (Tables)

Debt (Tables)	3 Months Ended
Debt (Tables)	Mar. 31, 2023
Debt
Schedule of debt	Maturity Interest March 31, December 31, Dates Rates 2023 2022 Term loans secured by all assets 04/2023 - 11/2030 3.25 - 6.00% $ 10,965,545 $ 11,341,934 Term loans secured by property and equipment 01/2024 - 10/2029 4.19 - 6.90% 10,815,089 9,299,197 Line of credit secured by all assets 04/2023 - 11/2025 4.50 - 6.50% 2,672,894 2,623,479 Term loans of consolidated Real Estate Entities 08/2023 - 03/2037 3.59 - 4.80% 13,886,997 15,068,920 Total 38,340,525 38,333,530 Less: unamortized debt issuance costs 103,134 112,802 Less: short-term lines of credit 2,672,893 2,623,479 Less: current portion of long-term debt 10,456,134 12,546,097 Total long-term debt $ 25,108,364 $ 23,051,152

Leases (Tables)

Leases (Tables)	3 Months Ended
Leases (Tables)	Mar. 31, 2023
Leases
Schedule of lease of property and equipment	Three Months Ended March 31, 2023 2022 Operating lease cost $ 948,515 $ 692,669 Finance lease cost: Amortization of right-of-use assets $ 2,484,275 $ 927,664 Interest on lease liabilities 2,688,520 980,619 Total finance lease cost $ 5,172,795 $ 1,908,283

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
Stock-based Compensation (Tables)	Mar. 31, 2023
Stock-based Compensation
Schedule of stock-based awards activity	Weighted Average Options Weighted Average Remaining Contractual Outstanding Exercise Price Life (Years) Options outstanding at December 31, 2022 5,147,770 $ 2.30 7.60 Options exercised - - Options cancelled - - Options outstanding at March 31, 2023 5,147,770 $ 2.32 7.35
Schedule of stock options outstanding	Expiration Number Number Exercise Date Outstanding Exercisable Price March 15, 2025 157,196 157,196 $ 4.47 January 27, 2027 180,000 180,000 1.50 May 11, 2027 350,000 350,000 1.50 June 6, 2027 3,600 3,600 36.25 August 16, 2027 25,000 25,000 2.51 January 28, 2028 180,000 180,000 1.61 January 27, 2030 296,865 296,865 1.50 February 28, 2030 95,794 95,794 1.25 June 30, 2030 117,056 117,056 1.45 August 4, 2029 40,480 40,480 5.56 January 28, 2031 1,000,000 1,000,000 1.61 February 28, 2031 200,000 200,000 2.00 September 9, 2031 1,934,779 1,934,779 2.75 September 9, 2031 410,000 410,000 2.75 December 17, 2031 157,000 157,000 3.50 Total 5,147,770 5,147,770

Equity (Tables)

Equity (Tables)	3 Months Ended
Equity (Tables)	Mar. 31, 2023
Equity
Schedule of common stock warrants	Weighted Average Warrants Weighted Average Remaining Contractual Outstanding Exercise Price Life (years) Warrants outstanding at December 31, 2022 11,033,015 $ 1.96 3.80 Warrants exercised (806,453) 1.55 Warrants expired (1,500) 1.55 Warrants outstanding at March 31, 2023 10,225,062 $ 1.99 3.53
Schedule of outstanding warrants	Expiration Number Number Exercise Date Outstanding Exercisable Price April 27, 2023 1,500 1,500 $ 25.00 December 31, 2024 554,873 554,873 6.67 October 31, 2025 16,250 16,250 1.25 October 31, 2025 1,566,451 1,566,451 1.55 February 26, 2026 288,235 288,235 4.00 July 31, 2026 2,532,900 2,532,900 1.55 February 1, 2027 650,000 650,000 1.55 May 31, 2027 4,614,853 4,614,853 1.75 Total 10,225,062 10,225,062

Earnings per Share (Tables)

Earnings per Share (Tables)	3 Months Ended
Earnings per Share (Tables)	Mar. 31, 2023
Earnings per Share
Schedule of earnings per share	Three Months Ended March 31, 2023 2022 Amounts attributable to Nutex Health Inc.: Numerator- Net income (loss) attributable to common stockholders $ (5,147,279) $ 21,442,843 Denominator: Weighted average shares used to compute basic and diluted EPS 650,915,693 592,791,712 Earnings (loss) per share: Basic $ (0.01) $ 0.04 Diluted $ (0.01) $ 0.04

Supplemental Cash Flows Infor_2

Supplemental Cash Flows Information (Tables)	3 Months Ended
Supplemental Cash Flows Information (Tables)	Mar. 31, 2023
Supplemental Cash Flows Information
Schedule of supplemental cash flows information	Three Months Ended March 31, 2023 2022 Cash paid for interest $ 430,643 $ 875,355 Cash paid for income taxes - 18,473 Non-cash investing and financing activities: Financed capital expenditures 2,709,019 - Acquisition of finance leases 18,798,667 9,937,104 Termination of operating and finance leases 2,818,498 - Exercise of warrants on cashless basis 702 - Issuance of common stock to Apollo Medical Holdings, Inc. 1,900,000 - Deconsolidation of Real Estate Entity 4,258,133 -

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
Segment Information (Tables)	Mar. 31, 2023
Segment Information
Schedule of segment information	Three Months Ended March 31, 2023 2022 Revenue from external customers: Hospital division $ 49,288,164 $ 79,127,242 Population health management division 7,041,253 - Total revenue $ 56,329,417 $ 79,127,242 Segment operating income: Hospital division 4,778,637 35,815,496 Population health management division 69,086 - Total segment operating income $ 4,847,723 $ 35,815,496 Capital expenditures: Hospital division 4,376,983 2,365,359 Real estate division - 6,226,464 Total capital expenditures $ 4,376,983 $ 8,591,823 Revenue from inter-segment activities: Real estate division $ 258,015 $ 4,045,969 Depreciation and amortization: Hospital division 3,564,022 2,396,861 Population health management division 388,047 - Real estate division 41,678 - Total depreciation and amortization $ 3,993,747 $ 2,396,861

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	3 Months Ended
Variable Interest Entities (Tables)	Mar. 31, 2023
Variable Interest Entities
Schedule of consolidated balance sheets	March 31, 2023 Real Estate Physician AHISP Entities LLCs IPA Current assets $ 4,671,762 $ 6,288,095 $ 8,016,463 Property and equipment, net 10,975,277 3,668 - Other long-term assets 19,634,442 - 16,254,462 Total assets $ 35,281,481 $ 6,291,763 $ 24,270,925 Current liabilities 1,038,381 5,400,568 24,240,245 Long-term liabilities 13,838,569 - 30,680 Total liabilities 14,876,950 5,400,568 24,270,925 Equity 20,404,531 891,195 - Total liabilities and equity $ 35,281,481 $ 6,291,763 $ 24,270,925 December 31, 2022 Real Estate Physician AHISP Entities LLCs IPA Current assets $ 3,466,811 $ 6,915,710 $ 6,641,448 Property and equipment, net 16,726,986 3,668 - Long-term assets 19,647,148 - 16,553,040 Total assets $ 39,840,945 $ 6,919,378 $ 23,194,488 Current liabilities 2,326,335 4,831,617 23,163,808 Long-term liabilities 15,019,633 - 30,680 Total liabilities 17,345,968 4,831,617 23,194,488 Equity 22,494,977 2,087,761 - Total liabilities and equity $ 39,840,945 $ 6,919,378 $ 23,194,488

Organization and Operations (De

Organization and Operations (Details)	3 Months Ended
Organization and Operations (Details)	Mar. 31, 2023 employee individual state facility shares
Number of hospital facilities \| facility	19
Number of states the company operates within \| state	8
Partner with physicians \| individual	900
Number of full time employees \| employee	1,200
Clinigence Holdings, Inc.
Conversion ratio	3.571428575
Common Stock
Common stock issued to Apollo Medical Holdings, Inc., (in shares)	1,000,000
Common Stock \| Merger Agreement
Common stock issued to Apollo Medical Holdings, Inc., (in shares)	592,791,712
Nutex Health Inc \| Merger Agreement \| Nutex Subsidiaries \| Nutex Health Holdco L L C
Ownership percentage	84%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	3 Months Ended		12 Months Ended
Summary of Significant Accounting Policies (Details)	Mar. 31, 2023 segment entity	Jun. 30, 2022 entity	Mar. 31, 2023 entity
Number of deconsolidated Real Estate Entities \| entity	1	17	18
Number of reportable segments \| segment	3
Physician LLC and Real Estate Entities [Member]
Ownership percentage	100%		100%
Associated Hispanic Physicians of So. California \| AHP Health Management Services Inc.
Percentage of control	100%

Merger of Nutex Health Holdco_3

Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc. - Total consideration in the merger (Details) - USD ($)		3 Months Ended
	Apr. 01, 2022	Mar. 31, 2023
Business combinations
Fair value of Clinigence common shares at $6.40 per share		$ 326,151,098
Fair value of Clinigence outstanding common stock options and warrants		110,543,915
Total consideration		$ 436,695,013
Clinigence Holdings, Inc.
Business combinations
Fair value per share	$ 6.40
Number of shares	50,961,109

Merger of Nutex Health Holdco_4

Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc. - Total purchase consideration to acquired assets and assumed liabilities (Details)	Mar. 31, 2023 USD ($)
Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc
Cash and cash equivalents	$ 12,716,228
Accounts receivable, net	2,127,076
Prepaid expenses and other current assets	127,384
Property and equipment, net	14,793
Right of use asset, net	86,989
Intangible assets, net	21,668,000
Goodwill	414,006,378
Accounts payable and accrued expenses	(3,966,100)
Deferred revenue	(92,111)
Convertible notes payable, net	(3,771,858)
Term note payable	(674,526)
Lease liability	(91,238)
Deferred tax liability	(5,456,002)
Assets acquired	$ 436,695,013

Merger of Nutex Health Holdco_5

Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc. - Supplemental pro forma financial information (Details)	3 Months Ended
	Mar. 31, 2022 USD ($) $ / shares
Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc
Revenue \| $	$ 85,336,417
Net income attributable to Nutex Health Inc. \| $	$ 7,180,154
Pro forma basic earnings per share \| $ / shares	$ 0.01
Pro forma diluted earnings per share \| $ / shares	$ 0.01

Merger of Nutex Health Holdco_6

Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Business combinations
Non-cash impairment charge		$ 398.1
Fair value adjustment of common stock options and warrants assumed	$ 10.3
Acquisition-related costs		$ 3.9
Pro forma loss	$ 14.2
Minimum
Business combinations
Useful life	5 years
Maximum
Business combinations
Useful life	16 years

Revenue - Disaggregate revenue

Revenue - Disaggregate revenue (Details) - USD ($)	3 Months Ended
Revenue - Disaggregate revenue (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue
Revenues	$ 56,329,417	$ 79,127,242
Hospital Division
Disaggregation of Revenue
Revenues	49,288,164	79,127,242
Population Health Management Division
Disaggregation of Revenue
Revenues	7,041,253
Net Patient Service Revenue \| Hospital Division
Disaggregation of Revenue
Revenues	54,137,235	$ 79,127,242
Capitation Revenue Net \| Population Health Management Division
Disaggregation of Revenue
Revenues	6,051,574
Management Fees \| Hospital Division
Disaggregation of Revenue
Revenues	(4,849,071)
Management Fees \| Population Health Management Division
Disaggregation of Revenue
Revenues	719,626
Saas Revenue \| Population Health Management Division
Disaggregation of Revenue
Revenues	$ 270,053

Revenue - Insurance Coverage (D

Revenue - Insurance Coverage (Details)	3 Months Ended
Revenue - Insurance Coverage (Details)	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue
Life Insurance Assumed Ratio	100%	100%
Insurance
Disaggregation of Revenue
Life Insurance Assumed Ratio	93%	96%
Self pay
Disaggregation of Revenue
Life Insurance Assumed Ratio	4%	3%
Workers compensation
Disaggregation of Revenue
Life Insurance Assumed Ratio	1%	1%
Medicare/Medicaid
Disaggregation of Revenue
Life Insurance Assumed Ratio	2%	0%

Revenue (Details)

Revenue (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Deferred revenue	$ 119,872	$ 99,143
Minimum
Percentage of net patient service revenue	90%

Property and Equipment - Catego

Property and Equipment - Categories (Details) - USD ($)	3 Months Ended
Property and Equipment - Categories (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment
Property and equipment, gross	$ 90,755,374	$ 95,106,230
Less: accumulated depreciation	(13,638,878)	(13,011,878)
Total property and equipment, net	$ 77,116,496	82,094,352
Buildings and improvements
Property, Plant and Equipment
Useful Life (years)	39 years
Property and equipment, gross	$ 9,086,826	8,521,996
Land
Property, Plant and Equipment
Property and equipment, gross	2,650,670	3,721,576
Leasehold improvements
Property, Plant and Equipment
Property and equipment, gross	$ 28,855,241	28,855,239
Leasehold improvements \| Minimum
Property, Plant and Equipment
Useful Life (years)	10 years
Leasehold improvements \| Maximum
Property, Plant and Equipment
Useful Life (years)	39 years
Construction in progress
Property, Plant and Equipment
Property and equipment, gross	$ 13,560,583	19,389,329
Medical equipment
Property, Plant and Equipment
Useful Life (years)	10 years
Property and equipment, gross	$ 29,220,485	28,744,664
Office furniture and equipment
Property, Plant and Equipment
Useful Life (years)	7 years
Property and equipment, gross	$ 2,860,680	2,860,680
Computer hardware and software
Property, Plant and Equipment
Useful Life (years)	5 years
Property and equipment, gross	$ 3,221,577	1,713,434
Vehicles
Property, Plant and Equipment
Useful Life (years)	5 years
Property and equipment, gross	$ 135,590	135,590
Signage
Property, Plant and Equipment
Useful Life (years)	10 years
Property and equipment, gross	$ 1,163,722	$ 1,163,722

Property and Equipment (Details

Property and Equipment (Details)	3 Months Ended			12 Months Ended
Property and Equipment (Details)	Mar. 31, 2023 USD ($) entity	Jun. 30, 2022 entity	Mar. 31, 2022 USD ($)	Mar. 31, 2023 entity
Property, Plant and Equipment
Number of deconsolidated Real Estate Entities \| entity	1	17		18
Depreciation and amortization	$ 3,993,747		$ 2,396,861
Property, Plant and Equipment [Member]
Property, Plant and Equipment
Depreciation and amortization	$ 1,123,053		$ 1,469,198

Intangible Assets - Components

Intangible Assets - Components (Details) - USD ($)	3 Months Ended		12 Months Ended
Intangible Assets - Components (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Finite-Lived Intangible Assets
Gross Carrying Amount	$ 22,350,649		$ 22,350,649
Accumulated amortization	1,545,678		1,159,259
Net Carrying Amount	20,804,971		21,191,390
Amortization of intangible assets	$ 386,419	$ 0
Minimum
Finite-Lived Intangible Assets
Weighted Average Useful Life (in years)	5 years
Maximum
Finite-Lived Intangible Assets
Weighted Average Useful Life (in years)	16 years
License
Finite-Lived Intangible Assets
Indefinite life intangible	$ 682,649		682,649
Member relationships
Finite-Lived Intangible Assets
Gross Carrying Amount	16,899,000		16,899,000
Accumulated amortization	1,126,599		844,950
Net Carrying Amount	$ 15,772,401		$ 16,054,050
Weighted Average Useful Life (in years)	15 years		15 years
Management contracts
Finite-Lived Intangible Assets
Gross Carrying Amount	$ 2,021,000		$ 2,021,000
Accumulated amortization	126,313		94,734
Net Carrying Amount	$ 1,894,687		$ 1,926,266
Weighted Average Useful Life (in years)	16 years		16 years
Customer contracts
Finite-Lived Intangible Assets
Gross Carrying Amount	$ 914,000		$ 914,000
Accumulated amortization	60,933		45,700
Net Carrying Amount	$ 853,067		$ 868,300
Weighted Average Useful Life (in years)	15 years		15 years
Trademarks
Finite-Lived Intangible Assets
Gross Carrying Amount	$ 1,425,000		$ 1,425,000
Accumulated amortization	150,033		112,525
Net Carrying Amount	$ 1,274,967		$ 1,312,475
Trademarks \| Minimum
Finite-Lived Intangible Assets
Weighted Average Useful Life (in years)	7 years		7 years
Trademarks \| Maximum
Finite-Lived Intangible Assets
Weighted Average Useful Life (in years)	12 years		12 years
PHP technology
Finite-Lived Intangible Assets
Gross Carrying Amount	$ 409,000		$ 409,000
Accumulated amortization	81,800		61,350
Net Carrying Amount	$ 327,200		$ 347,650
Weighted Average Useful Life (in years)	5 years		5 years

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Accrued Expenses and Other Current Liabilities
Accrued wages and benefits	$ 5,901,561	$ 4,235,167
Accrued taxes	3,461,054	1,029,790
Accrued other	799,551	975,856
Total accrued expenses and other current liabilities	$ 10,162,166	$ 6,240,813

Debt - Outstanding Debt (Detail

Debt - Outstanding Debt (Details) - USD ($)	3 Months Ended	12 Months Ended
Debt - Outstanding Debt (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument
Total	$ 38,340,525	$ 38,333,530
Less: unamortized debt issuance costs	103,134	112,802
Less: short-term lines of credit	2,672,893	2,623,479
Less: current portion of long-term debt	10,456,134	12,546,097
Total long-term debt	25,108,364	23,051,152
Term loans secured by all assets
Debt Instrument
Total	$ 10,965,545	$ 11,341,934
Term loans secured by all assets \| Minimum
Debt Instrument
Interest Rates (as percentage)	3.25%	3.25%
Term loans secured by all assets \| Maximum
Debt Instrument
Interest Rates (as percentage)	6%	6%
Term loans secured by property and equipment
Debt Instrument
Total	$ 10,815,089	$ 9,299,197
Term loans secured by property and equipment \| Minimum
Debt Instrument
Interest Rates (as percentage)	4.19%	4.19%
Term loans secured by property and equipment \| Maximum
Debt Instrument
Interest Rates (as percentage)	6.90%	6.90%
Line of credit secured by all assets
Debt Instrument
Total	$ 2,672,894	$ 2,623,479
Line of credit secured by all assets \| Minimum
Debt Instrument
Interest Rates (as percentage)	4.50%	4.50%
Line of credit secured by all assets \| Maximum
Debt Instrument
Interest Rates (as percentage)	6.50%	6.50%
Term loans of consolidated Real Estate Entities
Debt Instrument
Total	$ 13,886,997	$ 15,068,920
Term loans of consolidated Real Estate Entities \| Minimum
Debt Instrument
Interest Rates (as percentage)	3.59%	3.59%
Term loans of consolidated Real Estate Entities \| Maximum
Debt Instrument
Interest Rates (as percentage)	4.80%	4.80%

Debt (Details)

Debt (Details)	3 Months Ended		12 Months Ended
Debt (Details)	Mar. 31, 2023 USD ($) entity $ / shares shares	Jun. 30, 2022 entity	Mar. 31, 2023 USD ($) entity $ / shares
Debt Instrument
Number of deconsolidated Real Estate Entities \| entity	1	17	18
Debt instrument not in compliance with debt service coverage ratio	$ 1,000,000		$ 1,000,000
Remaining borrowing capacity	3,100,000		3,100,000
Convertible Notes Payable
Debt Instrument
Principle amount	$ 5,415,375		$ 5,415,375
Convertible notes, converted to shares \| shares	3,474,430
Conversion price per share \| $ / shares	$ 1.55		$ 1.55
Debt discount	$ 1,719,572		$ 1,719,572
Debt discount accretion period	4 months

Leases - Leases of property and

Leases - Leases of property and equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases
Operating lease cost	$ 948,515	$ 692,669
Finance lease cost:
Amortization of right-of-use assets	2,484,275	927,664
Interest on lease liabilities	2,688,520	980,619
Total finance lease cost	$ 5,172,795	$ 1,908,283

Stock-based Compensation (Detai

Stock-based Compensation (Details) - Equity Incentive 2022 Plan	3 Months Ended	12 Months Ended
	Mar. 31, 2023 $ / shares shares	Dec. 31, 2022 shares
Share-Based Payment Arrangement
Maximum aggregate number of shares that may be issued		5,000,000
Percentage company can increase stock-based compensation shares		5%
Shares available for issuance	2,416,221
Share-based award term	10 years
Share-based award vesting period	4 years
Multiplying factor	10
Share price \| $ / shares	$ 2.80

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-Based Awards Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share Based Compensation Arrangement Roll-Forward
Options, Outstanding, Beginning Balance	5,147,770
Options, Outstanding, Ending Balance	5,147,770	5,147,770
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning Balance	$ 2.30
Weighted Average Exercise Price, Ending Balance	$ 2.32	$ 2.30
Weighted Average Remaining Contractual Life (Years)	7 years 4 months 6 days	7 years 7 months 6 days

Stock-based Compensation - Opti

Stock-based Compensation - Options Outstanding (Details) - $ / shares	Mar. 31, 2023	Dec. 31, 2022	Apr. 01, 2022
Share-Based Payment Arrangement
Number Outstanding	5,147,770	5,147,770	6,500,010
Number Exercisable	5,147,770
Exercise Price	$ 2.32	$ 2.30
March 15, 2025
Share-Based Payment Arrangement
Number Outstanding	157,196
Number Exercisable	157,196
Exercise Price	$ 4.47
January 27, 2027
Share-Based Payment Arrangement
Number Outstanding	180,000
Number Exercisable	180,000
Exercise Price	$ 1.50
May 11, 2027
Share-Based Payment Arrangement
Number Outstanding	350,000
Number Exercisable	350,000
Exercise Price	$ 1.50
June 6, 2027
Share-Based Payment Arrangement
Number Outstanding	3,600
Number Exercisable	3,600
Exercise Price	$ 36.25
August 16, 2027
Share-Based Payment Arrangement
Number Outstanding	25,000
Number Exercisable	25,000
Exercise Price	$ 2.51
January 28, 2028
Share-Based Payment Arrangement
Number Outstanding	180,000
Number Exercisable	180,000
Exercise Price	$ 1.61
January 27, 2030
Share-Based Payment Arrangement
Number Outstanding	296,865
Number Exercisable	296,865
Exercise Price	$ 1.50
February 28, 2030
Share-Based Payment Arrangement
Number Outstanding	95,794
Number Exercisable	95,794
Exercise Price	$ 1.25
June 30, 2030
Share-Based Payment Arrangement
Number Outstanding	117,056
Number Exercisable	117,056
Exercise Price	$ 1.45
August 4, 2029
Share-Based Payment Arrangement
Number Outstanding	40,480
Number Exercisable	40,480
Exercise Price	$ 5.56
January 28, 2031
Share-Based Payment Arrangement
Number Outstanding	1,000,000
Number Exercisable	1,000,000
Exercise Price	$ 1.61
February 28, 2031
Share-Based Payment Arrangement
Number Outstanding	200,000
Number Exercisable	200,000
Exercise Price	$ 2
September 9, 2031
Share-Based Payment Arrangement
Number Outstanding	1,934,779
Number Exercisable	1,934,779
Exercise Price	$ 2.75
September 9, 2031
Share-Based Payment Arrangement
Number Outstanding	410,000
Number Exercisable	410,000
Exercise Price	$ 2.75
December 17, 2031
Share-Based Payment Arrangement
Number Outstanding	157,000
Number Exercisable	157,000
Exercise Price	$ 3.50

Equity (Details)

Equity (Details)		1 Months Ended	3 Months Ended
Equity (Details)	Apr. 01, 2022 shares	Mar. 31, 2023 USD ($) Vote $ / shares shares	Mar. 31, 2023 USD ($) Vote $ / shares shares	Dec. 31, 2022 $ / shares shares
Accumulated Other Comprehensive Income (Loss)
Common stock authorized		900,000,000	900,000,000	900,000,000
Common stock, par value \| $ / shares		$ 0.001	$ 0.001	$ 0.001
Number of votes entitled to each common stock holders \| Vote		1	1
Stock-based compensation expense \| $			$ 1,900,000
Warrants outstanding (in shares)		10,225,062	10,225,062
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss)
Common shares outstanding at the time of merger	50,961,109
Common stock issued to Apollo Medical Holdings, Inc., (in shares)			1,000,000
Common Stock [Member] \| Stock Purchase Agreement \| Apollo Medical Holdings, Inc.
Accumulated Other Comprehensive Income (Loss)
Common stock issued to Apollo Medical Holdings, Inc., (in shares)		1,000,000
Stock-based compensation expense \| $		$ 1,900,000
Common Stock Warrants
Accumulated Other Comprehensive Income (Loss)
Warrants outstanding (in shares)	12,401,240	10,225,062	10,225,062	11,033,015

Equity - Common Stock Warrants

Equity - Common Stock Warrants (Details) - $ / shares	3 Months Ended
Equity - Common Stock Warrants (Details) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Warrants Outstanding
Warrants outstanding, ending balance	10,225,062
Common Stock Warrants
Warrants Outstanding
Warrants outstanding, beginning balance	11,033,015
Warrants exercised	(806,453)
Warrants expired	(1,500)
Warrants outstanding, ending balance	10,225,062
Warrants Weighted Average Exercise Price
Warrants outstanding, beginning balance (in dollars per share)	$ 1.96
Warrants exercised (in dollars per share)	1.55
Warrants expired (in dollars per share)	1.55
Warrants outstanding, ending balance (in dollars per share)	$ 1.99
Warrants Weighted Average Remaining Contractual Life (years)	3 years 6 months 10 days	3 years 9 months 18 days

Equity - Schedule of Outstandin

Equity - Schedule of Outstanding Warrants (Details)	Mar. 31, 2023 $ / shares shares
Share-Based Payment Arrangement
Number Outstanding	10,225,062
Number Exercisable	10,225,062
Number of shares issued in satisfaction of cashless exercises	702,285
Warrants issued to purchase of common stock	806,453
April 27, 2023
Share-Based Payment Arrangement
Number Outstanding	1,500
Number Exercisable	1,500
Exercise Price \| $ / shares	$ 25
December 31, 2024
Share-Based Payment Arrangement
Number Outstanding	554,873
Number Exercisable	554,873
Exercise Price \| $ / shares	$ 6.67
October 31, 2025
Share-Based Payment Arrangement
Number Outstanding	16,250
Number Exercisable	16,250
Exercise Price \| $ / shares	$ 1.25
October 31, 2025
Share-Based Payment Arrangement
Number Outstanding	1,566,451
Number Exercisable	1,566,451
Exercise Price \| $ / shares	$ 1.55
February 26, 2026
Share-Based Payment Arrangement
Number Outstanding	288,235
Number Exercisable	288,235
Exercise Price \| $ / shares	$ 4
July 31, 2026
Share-Based Payment Arrangement
Number Outstanding	2,532,900
Number Exercisable	2,532,900
Exercise Price \| $ / shares	$ 1.55
February 1, 2027
Share-Based Payment Arrangement
Number Outstanding	650,000
Number Exercisable	650,000
Exercise Price \| $ / shares	$ 1.55
May 31, 2027
Share-Based Payment Arrangement
Number Outstanding	4,614,853
Number Exercisable	4,614,853
Exercise Price \| $ / shares	$ 1.75

Income Taxes - Effective tax ra

Income Taxes - Effective tax rate (Details)	3 Months Ended
Income Taxes - Effective tax rate (Details)	Mar. 31, 2023
Income Taxes
Effective tax rate	11.63%

Earnings per Share (Details)

Earnings per Share (Details) - USD ($)	3 Months Ended
Earnings per Share (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Numerator-
Net income (loss) attributable to common stockholders	$ (5,147,279)	$ 21,442,843
Denominator:
Weighted average shares used to compute basic EPS	650,915,693	592,791,712
Earnings (loss) per share:
Basic	$ (0.01)	$ 0.04
Diluted	$ (0.01)	$ 0.04
Dilutive effect of common stock options	5,147,770
Dilutive effect of common stock warrants	10,225,062

Supplemental Cash Flows Infor_3

Supplemental Cash Flows Information (Details) - USD ($)	3 Months Ended
Supplemental Cash Flows Information (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Supplemental Cash Flows Information
Cash paid for interest	$ 430,643	$ 875,355
Cash paid for income taxes		18,473
Non-cash investing and financing activities:
Financed capital expenditures	2,709,019
Acquisition of finance leases	18,798,667	$ 9,937,104
Termination of operating and finance leases	2,818,498
Exercise of warrants on cashless basis	702
Issuance of common stock to Apollo Medical Holdings, Inc.	1,900,000
Deconsolidation of Real Estate Entity	$ 4,258,133

Segment Information - Operation

Segment Information - Operations (Details)	3 Months Ended
Segment Information - Operations (Details)	Mar. 31, 2023 USD ($) segment	Mar. 31, 2022 USD ($)
Segment Reporting Information
Number of reportable segments \| segment	3
Total revenue	$ 56,329,417	$ 79,127,242
Total segment operating income	4,847,723	35,815,496
Total capital expenditures	4,376,983	8,591,823
Total depreciation and amortization	3,993,747	2,396,861
Intersegment Eliminations
Segment Reporting Information
Total revenue	258,015	4,045,969
Hospital Division \| Operating Segment
Segment Reporting Information
Total revenue	49,288,164	79,127,242
Total segment operating income	4,778,637	35,815,496
Total capital expenditures	4,376,983	2,365,359
Total depreciation and amortization	3,564,022	2,396,861
Population Health Management Division \| Operating Segment
Segment Reporting Information
Total revenue	7,041,253
Total segment operating income	69,086
Total depreciation and amortization	388,047
Real Estate Division \| Operating Segment
Segment Reporting Information
Total capital expenditures		$ 6,226,464
Total depreciation and amortization	$ 41,678

Related Party Transactions (Det

Related Party Transactions (Details)	3 Months Ended			12 Months Ended
Related Party Transactions (Details)	Mar. 31, 2023 USD ($) item entity	Jun. 30, 2022 entity	Mar. 31, 2022 USD ($)	Mar. 31, 2023 USD ($) entity item	Dec. 31, 2022 USD ($)
Related Party Transaction
Revenues, Net of Interest Expense			$ 1,506,650
Accounts Payable, Related Parties	$ 12,136			$ 12,136	$ 2,500
Revenue from related parties	158,851		412,554
Lease obligation payments	$ 3,519,345		2,883,681
Number of deconsolidated Real Estate Entities \| entity	1	17		18
Number of consolidated real estate entity \| item	2			2
Accounts payable - related parties	$ 3,925,297			$ 3,925,297	3,915,661
Physician LLCs
Related Party Transaction
Accounts Payable, Related Parties	2,488,212			2,488,212	2,058,701
Real Estate
Related Party Transaction
Revenues, Net of Interest Expense			553,259
E R Entities
Related Party Transaction
Accounts Receivable, Related Parties	538,259			538,259	538,184
E R Entities \| Managerial Services Agreements
Related Party Transaction
Repayments of related party debt	336,000		$ 323,194
Micro Hospital Holding LLC
Related Party Transaction
Accounts payable - related parties	$ 1,424,948			$ 1,424,948	$ 1,424,948

Variable Interest Entities - Ba

Variable Interest Entities - Balance sheet amounts (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022
Variable Interest Entities
Current assets	$ 88,667,107	$ 97,973,924
Property and equipment, net	77,116,496	82,094,352
Total assets	430,096,330	431,751,985
Current liabilities	47,878,789	54,862,969
Total liabilities	320,558,176	311,424,585
Equity	92,615,422	95,862,701
Total liabilities and equity	430,096,330	431,751,985
Real Estate Entities
Variable Interest Entities
Property and equipment, net	8,420,537		$ 98,086,690
Total liabilities	5,381,316		$ 69,638,778
Primary Beneficiary \| Real Estate Entities
Variable Interest Entities
Current assets	4,671,762	3,466,811
Property and equipment, net	10,975,277	16,726,986
Other long-term assets	19,634,442	19,647,148
Total assets	35,281,481	39,840,945
Current liabilities	1,038,381	2,326,335
Long-term liabilities	13,838,569	15,019,633
Total liabilities	14,876,950	17,345,968
Equity	20,404,531	22,494,977
Total liabilities and equity	35,281,481	39,840,945
Primary Beneficiary \| Physician LLCs
Variable Interest Entities
Current assets	6,288,095	6,915,710
Property and equipment, net	3,668	3,668
Total assets	6,291,763	6,919,378
Current liabilities	5,400,568	4,831,617
Total liabilities	5,400,568	4,831,617
Equity	891,195	2,087,761
Total liabilities and equity	6,291,763	6,919,378
Primary Beneficiary \| AHISIPA
Variable Interest Entities
Current assets	8,016,463	6,641,448
Other long-term assets	16,254,462	16,553,040
Total assets	24,270,925	23,194,488
Current liabilities	24,240,245	23,163,808
Long-term liabilities	30,680	30,680
Total liabilities	24,270,925	23,194,488
Total liabilities and equity	$ 24,270,925	$ 23,194,488

Variable Interest Entities (Det

Variable Interest Entities (Details)	3 Months Ended		12 Months Ended
Variable Interest Entities (Details)	Mar. 31, 2023 USD ($) entity	Jun. 30, 2022 USD ($) entity	Mar. 31, 2023 USD ($) entity	Dec. 31, 2022 USD ($)
Number of deconsolidated Real Estate Entities \| entity	1	17	18
Number of real estate entities consolidated \| entity	2
Fixed assets	$ 77,116,496		$ 77,116,496	$ 82,094,352
Other assets	422,926		422,926	423,426
Liabilities	320,558,176		320,558,176	311,424,585
Equity attributable to noncontrolling interests	16,922,732		16,922,732	$ 24,464,699
Real Estate Entities
Cash	1,039,156	$ 2,421,212	1,039,156
Fixed assets	8,420,537	98,086,690	8,420,537
Other assets	179,846	533,874	179,846
Liabilities	5,381,316	69,638,778	5,381,316
Equity attributable to noncontrolling interests	$ 4,258,133	$ 31,402,998	$ 4,258,133

Subsequent Events (Details)

Subsequent Events (Details)			3 Months Ended
Subsequent Events (Details)	Apr. 11, 2023 USD ($) D $ / shares	Apr. 01, 2023 USD ($) shares	Mar. 31, 2023 USD ($) shares	Mar. 31, 2022 USD ($)	Apr. 10, 2023 shares
Subsequent Events
Proceeds from pre-paid advance			$ 49,414	$ 2,044,765
Number of shares issued in satisfaction of cashless exercises \| shares			702,285
Warrants issued to purchase of common stock \| shares			806,453
Subsequent Event [Member]
Subsequent Events
Number of shares issued in satisfaction of cashless exercises \| shares					566,042
Warrants issued to purchase of common stock \| shares					650,000
Subsequent Event [Member] \| RSUs \| Certain employees
Subsequent Events
Issued shares \| shares		604,158
Value of shares		$ 610,210
Subsequent Event [Member] \| RSUs \| Certain employees \| Vests on April 1, 2023
Subsequent Events
Shares vested \| shares		214,719
Subsequent Event [Member] \| RSUs \| Certain employees \| Vests on March 1, 2024
Subsequent Events
Shares vested \| shares		194,719
Subsequent Event [Member] \| RSUs \| Certain employees \| Vests on March 1, 2025
Subsequent Events
Shares vested \| shares		194,719
Subsequent Event [Member] \| Pre-Paid Advance Agreement with Yorkville \| Yorkville
Subsequent Events
Maximum amount of advance may request	$ 25,000,000
Percentage of the face amount for issue	90%
Maximum amount of pre-paid advances	$ 100,000,000
Credit period	18 months
Initial pre-paid advance amount with expenses	$ 15,000,000
Proceeds from pre-paid advance	12,800,000
Agreed pre-paid advance based on conditions	10,000,000
Maximum outstanding balance for receipt of additional advance	$ 1,000,000
Number of trading days considered for volume weighted average price	10 days
Volume weighted average price per share \| $ / shares	$ 0.60
Initial pre-paid advances per share \| $ / shares	$ 1
Percentage of volume weighted average price	100%
Average percentage of volume weighted average price	92%
Pre-paid advances per share	0.1851%
Threshold number of specified trading days \| D	7
Principal balance	$ 2,000,000
Principal balance converted to common stock \| shares		3,856,267
Subsequent Event [Member] \| Pre-Paid Advance Agreement with Yorkville \| Yorkville \| Minimum
Subsequent Events
Pre-paid advance amount	5,000,000
Subsequent Event [Member] \| Pre-Paid Advance Agreement with Yorkville \| Yorkville \| Maximum
Subsequent Events
Pre-paid advance amount	$ 25,000,000